Triducard MB, modified-release pills 35mg, 60pcs

Composition

one modified release film-coated tablet contains the Active ingredient trimetazidine dihydrochloride 35 mg. Auxiliary substances: hypromellose (metocel K 4M Premium EP) – 54 mg; microcrystalline cellulose-118 mg; colloidal silicon dioxide (aerosil) – 1 mg; magnesium stearate-1 mg; Shell composition: Hydroxypropylmethylcellulose (hypromellose) – 4,628 mg; talc-0,357 mg; titanium dioxide-1,002 mg; macrogol (polyethylene oxide 4000) – 1,002 mg; dye azorubin (acid red 2C for pharmaceutical purposes) – 0,011 mg. Description: tablets covered with a film-coated pink color, round, biconvex. 30 tablets of 35 mg

Pharmacological action

Pharmacotherapeutic group:

antihypoxant agent.

ATX code: [C 01 EV 15]

Pharmacological properties

Pharmacodynamics :

Trimetazidine has an antianginal, antihypoxic effect. Directly affecting cardiomyocytes and brain neurons, it optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation).

Supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinine. In conditions of acidosis, it normalizes the functioning of ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions.

Reduces intracellular acidosis and phosphate concentrations due to myocardial ischemia and reperfusion. It prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents neutrophil activation in the ischemic zone, increases the duration of the electrical potential, reduces the release of creatine phosphokinase from cells and the severity of ischemic myocardial damage.

When angina reduces the frequency of attacks (reduces the intake of nitrates), after 2 weeks of treatment increases tolerance to physical activity, decreases blood pressure drops. Improves hearing and results of vestibular tests in patients, reduces dizziness and tinnitus. In vascular pathology, the eye restores the functional activity of the retina.

Pharmacokinetics:  

After oral use, trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability – 90%.

The time to reach the maximum concentration in blood plasma is 2 hours. The maximum concentration after a single dose of 35 mg of trimetazidine is about 55 ng / ml. Easily passes through histohematic barriers. The half-life (T 1/2) is 4.5-5 hours. Binding to plasma proteins is 16%. It is excreted from the body by the kidneys (about 60% – unchanged).

Indications

• Coronary heart disease: prevention of angina attacks (in complex therapy);
• Vertigo of vascular origin;
• Cochlea-vestibular disorders of an ischemic nature (tinnitus, hearing impairment);
• Chorioretinal vascular disorders.

Use during pregnancy and lactation

Tridukard is contraindicated for use during pregnancy and lactation.

Contraindications

• Hypersensitivity to any component of the drug Tridukard;
• Severe liver function disorders;
• Renal insufficiency (creatinine clearance below 15 ml / min);
• Pregnancy;
• Breast-feeding period;
• Age up to 18 years (efficacy and safety have not been established).

Side effects

Allergic reactions: pruritus of the skin.

From the digestive system: rarely-gastralgia, nausea, vomiting.

From the cardiovascular system: rarely-headache, palpitations.

How to take, course of use and dosage

Inside, while eating. The recommended dosage regimen is 2 tablets (70 mg) per day, in 2 divided doses.

Course of treatment according to the doctor’s recommendation.

Special instructions

The drug is not intended for relief of angina attacks!

If an angina attack develops, treatment should be reviewed and adapted (drug therapy or revascularization).

The use of the drug does not affect the ability to drive a car and perform work that requires a high speed of mental and physical reactions.

Form of production

Modified release film-coated tablets

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf

life is 3 years.

Active ingredient

Trimetazidine

Conditions of release from pharmacies

By prescription

Dosage form

long-acting tablets

Description

For adults as directed by your doctor

Indications

Angina, Vascular diseases of the eyes